仟源医药(300254) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥189,493,463.31, representing a 3.44% increase compared to ¥183,185,038.02 in the same period last year[5] - Net profit attributable to shareholders reached ¥18,284,352.36, a significant increase of 947.75% from a loss of ¥2,156,812.13 in the previous year[5] - The net cash flow from operating activities was ¥35,485,717.14, marking a 640.55% increase from a negative cash flow of ¥6,564,702.62 in the same period last year[5] - Basic and diluted earnings per share were both ¥0.0757, compared to a loss of ¥0.0089 per share in the previous year, reflecting a 950.56% improvement[5] - The company's net profit for Q1 2024 reached CNY 24,945,683.88, a significant increase compared to CNY 2,981,088.59 in Q1 2023, representing a growth of approximately 736%[26] - Operating profit for Q1 2024 was CNY 18,435,645.08, compared to a loss of CNY 2,612,624.93 in the same period last year, indicating a turnaround in operational performance[26] - The total comprehensive income for Q1 2024 was CNY 24,945,683.88, compared to CNY 2,981,088.59 in the same quarter last year, indicating a substantial improvement[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,476,233,754.13, an increase of 3.01% from ¥1,433,075,413.12 at the end of the previous year[5] - Total liabilities increased to CNY 672,856,013.43 from CNY 654,643,356.30, indicating an increase of about 2.3%[24] - The total equity attributable to shareholders of the parent company improved to CNY 618,416,875.06 from CNY 600,132,522.70, marking an increase of approximately 3.0%[24] Research and Development - The company's R&D expenses for the period were ¥12,048,200, representing a 34.95% increase compared to the same period last year[8] - Research and development expenses increased to CNY 12,048,160.13 in Q1 2024, up from CNY 8,927,664.99 in Q1 2023, reflecting a year-over-year growth of approximately 35%[26] - The company plans to continue investing in R&D and market expansion to drive future growth, although specific new products or technologies were not detailed in the report[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,531[12] - The largest shareholder, Weng Zhangguo, holds 6.53% of shares, totaling 15,772,409 shares[12] - Shareholder Zhao Qun holds 5.55% of shares, totaling 13,401,892 shares, with 10,051,419 shares under lock-up[12] - The total number of restricted shares at the end of the period is 16,596,968 shares, all under executive lock-up[15] - The top ten shareholders include both domestic and foreign individuals, with varying percentages of ownership[12] - The company has not reported any changes in the lending or borrowing of shares among the top ten shareholders[13] - The company has not disclosed any related party relationships among the top ten shareholders[12] Cash Flow and Financing - The net cash flow from financing activities was ¥11,056,300, an increase of 211.76% compared to the previous year[10] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 131,907,074.24, down from CNY 341,918,562.95 at the end of Q1 2023[30] - The company incurred financial expenses of CNY 3,743,632.23 in Q1 2024, a decrease from CNY 11,252,129.49 in Q1 2023, showing a reduction of approximately 67%[26] Operational Highlights - The company reported a significant increase in non-operating income, with government subsidies amounting to ¥2,409,636.37, contributing to overall profitability[6] - Total revenue from sales of goods and services in Q1 2024 was CNY 197,655,753.57, compared to CNY 184,433,813.87 in Q1 2023, marking an increase of about 7%[30] - The total operating costs for the current period amount to CNY 176,063,821.72, down from CNY 185,981,096.81 in the previous period, indicating a decrease of about 5.0%[25] Corporate Governance - The company plans to issue new shares to specific investors as part of its capital raising strategy, as approved in the board meeting[19] - The company has revised its governance structure and related policies to comply with the latest regulations, enhancing operational management[19] Other Information - The company provided a joint guarantee for a loan of RMB 40 million for Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. with a term of 2 years[16] - The subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. has been re-certified as a high-tech enterprise[17] - The company has returned RMB 50 million of temporarily used funds to its special fundraising account within 12 months[17] - Accounts receivable decreased to CNY 99,343,672.36 from CNY 107,802,272.28, representing a decline of approximately 7.5%[22] - Inventory increased to CNY 127,561,035.80 from CNY 120,831,093.39, showing an increase of about 5.7%[23]